[et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.27.4″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]<\/p>\n
Paris, January 2026 \u2013 Delbert Pharma, a French pharmaceutical company dedicated to safeguarding essential medicines, announces a partnership with the Kent Athlone Pharma Group for the Distribution and Marketing of the injectable aztreonam (Azactam\u00ae) in the UK and Ireland<\/strong><\/p>\n Delbert Pharma acquired Azactam\u00ae from Bristol Myers Squibb in December 2024.<\/p>\n Appointing Kent Athlone Pharma Group to market & distribute Azactam\u00ae in the UK and Ireland, reflects the company\u2019s strong track record and capabilities commercialising specialty hospital medicines.<\/p>\n For Kent Athlone Pharma Group, the addition of Azactam\u00ae injection enhances and compliments the company\u2019s existing anti-infective injectable portfolio.<\/p>\n <\/b>\u201cPartnering with Kent Athlone Pharma Group marks a significant step in Delbert Pharma\u2019s international growth strategy. We are proud to bring Azactam\u00ae back to patients in the UK and Ireland with a trusted partner who shares our commitment to ensuring continuous access to essential hospital medicines.\u201d<\/p>\n stated Eric Fidelin, Executive General Director of Delbert Pharma.<\/p>\n \u201cThe addition of Azactam\u00ae injection enhances and compliments the company\u2019s existing anti-infective injectable portfolio. We look forward to working with Delbert Pharma to ensure continued access for patients in the UK and Ireland to this important medicine\u201d. <\/i><\/p>\n said David Wright Chief Business Officer of the Kent Athlone Pharma Group<\/p>\n About Delbert Pharma<\/b><\/p>\n Delbert Pharma is an independent French pharmaceutical company founded in 2013 and a mission-driven company since 2023, dedicated to preserving essential medicines for the stability of healthcare systems. Delbert Pharma offers a broad range of treatments in infectious diseases, neurology, and onco-haematology, addressing critical medical needs in Europe and beyond. The company is strongly committed to combating medicine shortages and fostering pharmaceutical reindustrialization. <\/p>\n About Kent Athlone Pharma Group [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" Paris, January 2026 \u2013 Delbert Pharma, a French pharmaceutical company dedicated to safeguarding essential medicines, announces a partnership with the Kent Athlone Pharma Group for the Distribution and Marketing of the injectable aztreonam (Azactam\u00ae) in the UK and Ireland Delbert Pharma acquired Azactam\u00ae from Bristol Myers Squibb in December 2024. Appointing Kent Athlone Pharma Group […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"categories":[110],"tags":[],"class_list":["post-4779","post","type-post","status-publish","format-standard","hentry","category-niet-geclassificeerd"],"yoast_head":"\n
Kent Athlone Pharma Group is a privately owned asset-light, European specialty pharmaceutical company with offices in the UK (Corporate HQ) and Ireland (EU office). The company is focused on developing, licensing, launching, and commercialising Value Added Medicines to meet the needs of customers and patients in the UK, Ireland and Europe. <\/p>\n